Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...

Benger will take over from Roberts – who was named CEO in 2021 and announced her decision to step down in the summer – on ...

At Frontiers Health 2025, the conversation around global brand launches was evolving rapidly – and EVERSANA and its agency ...

The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...

The AI floodgates are open. The race belongs to those who can scale speed without losing traceability, and next year the AI ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use ...

The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the ...

Grassmuno – also known as Grass MATA MPL – is additionally the first subcutaneous grass pollen allergy immunotherapy to be cleared by the Paul Ehrlich Institute (PEI), Germany's medicines regulator, ...

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...